Who is sponsoring NCT05422092?

NCT05422092 is sponsored by First Affiliated Hospital Xi'an Jiaotong University.

What condition does NCT05422092 study?

NCT05422092 studies Type 2 Diabetes Mellitus With Complication.

What drugs are being tested in NCT05422092?

Interventions: Canagliflozin, Pioglitazone.

What is the status of NCT05422092?

NCT05422092 is currently UNKNOWN.

Last reviewed 2022-09-18 · How we verify

Therapeutic Effects of Canagliflozin on the Liver Inflammation Damage and Lipoprotein Metabolism in Patients With Type 2 Diabetes Mellitus Combined With Nonalcoholic Fatty Liver Disease

NCT05422092 NA UNKNOWN

Type 2 diabetes mellitus (T2DM) is always accompanied with nonalcoholic fatty liver disease (NAFLD).This prospective, randomized controlled intervention study was designed to reveal the potential clinical application and underlying mechanisms of canagliflozin in the treatment of type 2 diabetes combined with nonalcoholic fatty liver disease.

Details

Lead sponsor	First Affiliated Hospital Xi'an Jiaotong University
Phase	NA
Status	UNKNOWN
Enrolment	80
Start date	2022-09-20
Completion	2023-12

Conditions

Type 2 Diabetes Mellitus With Complication

Interventions

Canagliflozin
Pioglitazone

Primary outcomes

Plasma cholesteryl ester transfer protein(CETP) concentration in ug/mL — 24 weeks after the date of enrollment
Measurements of liver inflammation and damage
The activity of CEPT in pmol/mL/min — 24 weeks after the date of enrollment
Measurements of liver inflammation and damage